Found: 44
Select item for more details and to access through your institution.
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019.
- Published in:
- PLoS Medicine, 2023, v. 20, n. 11, p. 1, doi. 10.1371/journal.pmed.1004309
- By:
- Publication type:
- Article
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 1, p. e225218, doi. 10.1001/jamahealthforum.2022.5218
- By:
- Publication type:
- Article
Medicare Spending on Drugs With Accelerated Approval, 2015-2019.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 12, p. 1, doi. 10.1001/jamahealthforum.2021.3937
- By:
- Publication type:
- Article
Estimating Rebates and Other Discounts Received by Medicare Part D.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 6, p. 1, doi. 10.1001/jamahealthforum.2021.0626
- By:
- Publication type:
- Article
Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 7, p. e2419873, doi. 10.1001/jamanetworkopen.2024.19873
- By:
- Publication type:
- Article
Trends in Medicare Part D Inhaler Spending: 2012-2018.
- Published in:
- 2021
- By:
- Publication type:
- letter
Trends in Medicare Part D Inhaler Spending: 2012–2018.
- Published in:
- Annals of the American Thoracic Society, 2021, v. 18, n. 3, p. 445
- By:
- Publication type:
- Article
Medicare Negotiation's Drug Reformulation Problem.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases.
- Published in:
- Journal of Law & the Biosciences, 2022, v. 9, n. 1, p. 1, doi. 10.1093/jlb/lsac001
- By:
- Publication type:
- Article
Drug Prices, Rebates, and Discounts.
- Published in:
- 2020
- By:
- Publication type:
- Letter to the Editor
Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
- Published in:
- Drug Safety, 2021, v. 44, n. 7, p. 743, doi. 10.1007/s40264-021-01070-2
- By:
- Publication type:
- Article
Coverage of New Drugs in Medicare Part D.
- Published in:
- Milbank Quarterly, 2022, v. 100, n. 2, p. 562, doi. 10.1111/1468-0009.12565
- By:
- Publication type:
- Article
Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
- Published in:
- Milbank Quarterly, 2021, v. 99, n. 1, p. 240, doi. 10.1111/1468-0009.12507
- By:
- Publication type:
- Article
Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys.
- Published in:
- JAMA Network Open, 2019, v. 2, n. 7, p. e197591, doi. 10.1001/jamanetworkopen.2019.7591
- By:
- Publication type:
- Article
Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
- Published in:
- Pediatric Blood & Cancer, 2024, v. 71, n. 9, p. 1, doi. 10.1002/pbc.31158
- By:
- Publication type:
- Article
Use of Track One Prioritized Examination for Pharmaceutical Patents.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 7, p. e241886, doi. 10.1001/jamahealthforum.2024.1886
- By:
- Publication type:
- Article
Outcomes of the 340B Drug Pricing Program: A Scoping Review.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 11, p. e233716, doi. 10.1001/jamahealthforum.2023.3716
- By:
- Publication type:
- Article
Delivery Device Patents on GLP-1 Receptor Agonists.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 9, p. 794, doi. 10.1001/jama.2024.0919
- By:
- Publication type:
- Article
Biologic Patent Thickets and Terminal Disclaimers.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 4, p. 355, doi. 10.1001/jama.2023.25389
- By:
- Publication type:
- Article
Ancillary Product Patents to Extend Biologic Patent Life.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 21, p. 2117, doi. 10.1001/jama.2023.19547
- By:
- Publication type:
- Article
The Problem of Limited-Supply Agreements for Medicare Price Negotiation.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 13, p. 1223, doi. 10.1001/jama.2023.17208
- By:
- Publication type:
- Article
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 7, p. 650, doi. 10.1001/jama.2023.13872
- By:
- Publication type:
- Article
Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 5, p. 469, doi. 10.1001/jama.2023.11525
- By:
- Publication type:
- Article
Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 1, p. 87, doi. 10.1001/jama.2022.19691
- By:
- Publication type:
- Article
Over-the-Counter Availability of Rescue Inhalers for Asthma-Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 328, n. 2, p. 216, doi. 10.1001/jama.2022.8775
- By:
- Publication type:
- Article
Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone–Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 1, p. 1, doi. 10.7326/L23-0429
- By:
- Publication type:
- Article
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone–Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 8, p. 1047, doi. 10.7326/M23-0615
- By:
- Publication type:
- Article
Trust in the Food and Drug Administration: A National Survey Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 2, p. 408, doi. 10.1002/cpt.3292
- By:
- Publication type:
- Article
Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 11, p. e2135362, doi. 10.1001/jamanetworkopen.2021.35362
- By:
- Publication type:
- Article
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 5, p. e218816, doi. 10.1001/jamanetworkopen.2021.8816
- By:
- Publication type:
- Article
Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD.
- Published in:
- Nature Biotechnology, 2022, v. 40, n. 9, p. 1319, doi. 10.1038/s41587-022-01451-7
- By:
- Publication type:
- Article
The Rise and Fall of the Insulin Pricing Bubble.
- Published in:
- 2023
- By:
- Publication type:
- Opinion
Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e237467, doi. 10.1001/jamanetworkopen.2023.7467
- By:
- Publication type:
- Article
Leah Z. Rand, Daniel P. Carpenter, Aaron S. Kesselheim, Anushka Bhaskar, Jonathan J. Darrow, and William B. Feldman Reply.
- Published in:
- Hastings Center Report, 2024, v. 54, n. 2, p. 44, doi. 10.1002/hast.1579
- By:
- Publication type:
- Article
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines.
- Published in:
- Hastings Center Report, 2023, v. 53, p. S60, doi. 10.1002/hast.1525
- By:
- Publication type:
- Article
Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
- Published in:
- JAMA Internal Medicine, 2024, v. 184, n. 1, p. 63, doi. 10.1001/jamainternmed.2023.6293
- By:
- Publication type:
- Article
Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
- Published in:
- JAMA Internal Medicine, 2023, v. 183, n. 7, p. 685, doi. 10.1001/jamainternmed.2023.1245
- By:
- Publication type:
- Article
Assessment of Prices for Cardiovascular Tests and Procedures at Top-Ranked US Hospitals.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 3, p. 297, doi. 10.1001/jamadermatol.2023.5857
- By:
- Publication type:
- Article